Celsion Co. (CLSN) CEO Michael H. Tardugno Acquires 7,500 Shares of Stock

Celsion Co. (NASDAQ:CLSN) CEO Michael H. Tardugno acquired 7,500 shares of the business’s stock in a transaction dated Monday, October 29th. The shares were purchased at an average price of $2.06 per share, with a total value of $15,450.00. Following the transaction, the chief executive officer now owns 27,700 shares of the company’s stock, valued at $57,062. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Celsion stock opened at $2.06 on Wednesday. The stock has a market cap of $40.48 million, a PE ratio of -0.86 and a beta of 1.12. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.48. Celsion Co. has a twelve month low of $1.75 and a twelve month high of $3.96.

Celsion (NASDAQ:CLSN) last issued its quarterly earnings data on Tuesday, August 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.19). The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million. Celsion had a negative net margin of 4,479.42% and a negative return on equity of 109.99%. Analysts anticipate that Celsion Co. will post -1.17 earnings per share for the current fiscal year.



A hedge fund recently raised its stake in Celsion stock. BlackRock Inc. raised its position in Celsion Co. (NASDAQ:CLSN) by 72.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,844 shares of the biotechnology company’s stock after buying an additional 48,194 shares during the quarter. BlackRock Inc. owned 0.65% of Celsion worth $339,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 4.76% of the company’s stock.

Separately, Zacks Investment Research lowered Celsion from a “hold” rating to a “sell” rating in a research report on Monday, August 20th.

About Celsion

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer.

See Also: How much money do you need to begin day trading?

Insider Buying and Selling by Quarter for Celsion (NASDAQ:CLSN)

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply